Thor Medical ASA Logo

Thor Medical ASA

Sustainably produces alpha-emitters from thorium for cancer therapies, without nuclear reactors.

NANOV | OL

Overview

Corporate Details

ISIN(s):
NO0010597883 (+1 more)
LEI:
5967007LIEEXZXG6DK30
Country:
Norway
Address:
Drammensveien 167, 0277 Oslo
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Thor Medical ASA is an emerging producer and supplier of radionuclides for medical use, specializing in alpha-particle emitters for targeted alpha therapies in oncology. The company has developed a proprietary technology for manufacturing these isotopes by separating naturally occurring radioactive decay products from thorium. This novel process eliminates the need for nuclear reactors or cyclotrons, providing a more efficient, cost-competitive, and environmentally sustainable alternative to traditional production methods.

Social Media

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-11-11 23:15
Director's Dealing
Thor Medical - Issuance of RSU shares to members of the board - Attachment: 202…
Norwegian 93.5 KB
2025-11-11 23:15
Director's Dealing
Thor Medical - Issuance of RSU shares to members of the board - Attachment: 202…
Norwegian 93.0 KB
2025-11-11 23:15
Director's Dealing
Thor Medical - Issuance of RSU shares to members of the board - Attachment: Dow…
Norwegian 50.5 KB
2025-11-11 23:15
Remuneration Information
Thor Medical - Issuance of RSU shares to members of the board
English 2.5 KB
2025-11-06 07:30
Regulatory News Service
Thor Medical and Telix Pharmaceuticals sign strategic supply agreement for thor…
English 56.4 KB
2025-11-06 07:30
Regulatory News Service
Thor Medical and Telix Pharmaceuticals sign strategic supply agreement for thor…
English 6.2 KB
2025-08-22 08:00
Report Publication Announcement
Invitation to presentation of Thor Medical ASA's 1H 2025 on Friday 29 August at…
English 50.3 KB
2025-08-22 08:00
Report Publication Announcement
Invitation to presentation of Thor Medical ASA's 1H 2025 on Friday 29 August at…
English 2.1 KB
2025-08-04 07:30
Business and Financial Review
Thor Medical and AdvanCell expand strategic supply agreement for Thorium-228 - …
English 64.1 KB
2025-08-04 07:30
Business and Financial Review
Thor Medical and AdvanCell expand strategic supply agreement for Thorium-228
English 7.7 KB
2025-08-01 08:58
Declaration of Voting Results & Voting Rights Announcements
Thor Medical ASA - Share capital increase in relation to Subsequent Offering is…
English 46.1 KB
2025-08-01 08:58
Share Issue/Capital Change
Thor Medical ASA - Share capital increase in relation to Subsequent Offering is…
English 2.0 KB
2025-07-04 10:41
Share Issue/Capital Change
Thor Medical ASA: Final results of the Subsequent Offering - Attachment: Downlo…
Norwegian 59.1 KB
2025-07-04 10:41
Share Issue/Capital Change
Thor Medical ASA: Final results of the Subsequent Offering
Norwegian 10.1 KB
2025-07-03 07:00
Share Issue/Capital Change
Thor Medical ASA: The Subscription Period in the Subsequent Offering ends at 16…
Norwegian 62.0 KB

Automate Your Workflow. Get a real-time feed of all Thor Medical ASA filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Thor Medical ASA

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Thor Medical ASA via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Upstream Bio, Inc. Logo
Developing a monoclonal antibody for severe inflammatory and respiratory diseases.
United States of America
UPB
UroGen Pharma Ltd. Logo
Develops non-surgical therapies for urological cancers using proprietary hydrogel technology.
United States of America
URGN
Valbiotis Logo
Develops clinically tested, plant-based supplements for metabolic & cardiovascular health.
France
ALVAL
Valneva SE Logo
Develops and commercializes vaccines for infectious diseases like chikungunya, Lyme, and Zika.
France
VLA
Vanda Pharmaceuticals Inc. Logo
Develops and commercializes innovative therapies for central nervous system disorders.
United States of America
VNDA
Vaxcell-Bio Therapeutics Logo
Develops CAR-T and CAR-NK immunotherapies for solid tumors and canine lymphoma.
South Korea
323990
Vaxcyte, Inc. Logo
A clinical-stage company developing broad-spectrum vaccines for bacterial infectious diseases.
United States of America
PCVX
VENTURE LIFE GROUP PLC Logo
Develops, manufactures, and distributes consumer self-care products and medical devices globally.
United Kingdom
VLG
Ventyx Biosciences, Inc. Logo
Clinical-stage biopharma developing oral therapies for autoimmune, inflammatory & neuro diseases.
United States of America
VTYX
Verastem, Inc. Logo
Develops cancer medicines targeting the RAS/MAPK pathway, with an approved therapy for ovarian cancer.
United States of America
VSTM

Talk to a Data Expert

Have a question? We'll get back to you promptly.